Symbicort®
Budesonide/Formoterol is an ICS/LABA combination for asthma and COPD. Also approved for as-needed use (SMART approach) in asthma management.
| Dosage Form | Inhaler (MDI / DPI) |
| Strength | 80/4.5, 160/4.5, 320/9 mcg |
| Storage | Store at 20–25°C. |
| Category | Respiratory |
| Availability | Available for Transfer |
Asthma (maintenance and reliever therapy); COPD (maintenance treatment to reduce exacerbations).
Budesonide (ICS) suppresses inflammation through glucocorticoid receptor activation. Formoterol (LABA) provides rapid and sustained bronchodilation via beta-2 receptor stimulation.
Each Burrard Pharmaceuticals technology transfer package for Budesonide / Formoterol includes comprehensive documentation and support:
Complete formulation with manufacturing parameters, excipient specifications, and process controls.
Validated methods for assay, impurities, dissolution, and stability-indicating analysis.
Market-ready regulatory dossier sections for a named territory, scoped per programme.
ICH-compliant stability studies (accelerated and long-term) with detailed protocols.
Scale-up procedures, batch records, equipment specifications, and in-process controls.
Direct advisory access to formulation scientists and regulatory specialists throughout transfer.
Scope and timing for the complete know-how package are confirmed in writing after a confidentiality agreement. Book a consultation to discuss your specific requirements.